european and us drugs groups are threatening to dominate the world's market leaving their japanese counterparts trailing according to a study by datamonitor the london-based strategy consultants in particular the european groups dominance will be driven by their innovative research and development new products and international marketing strength only three japanese companies takeda sankyo and shionogi are among the world's top 25 drugs groups and none is in the top 10 japan ran a trade deficit of more than pounds 800 m in 1989 repeated price cuts implemented by the ministry of health and welfare have seriously handicapped the japanese industry while drug prices in the us increased by 40 per cent between 1982 and 1988, those in japan fell 39 per cent in 1991 alone shionogi and fujisawa suffered average price cuts of 9.5 per cent and 9 per cent respectively japanese groups have been hit disproportionately because of their dependence on the domestic market takeda the largest japanese group generates 98.6 per cent of its turnover in japan japanese spending on research and development has doubled in the past 10 years though sales increased only 50 per cent the datamonitor report warns however that the japanese r d push may come too late because of increasing penetration of the japanese market by western drugs groups this it argues is likely to accelerate a consolidation of the japanese industry the japanese pharmaceutical market 1992-1995 datamonitor 106 baker street london w1m 1 la 071 625 85 48 pounds 695